CriticalClass Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)×Atypical antipsychotic – indole derivative
Updated · Methodology
Mechanism
Both drugs prolong the QT interval: ziprasidone causes mild to moderate, dose-dependent prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Quinidine, like other class IA antiarrhythmics, prolongs the corrected QT interval (QTc) in a dose-related way, which can lead to life-threatening torsade de pointes (quinidine label, US Food and Drug Administration, FDA). No studies have been done with ziprasidone and other QT-prolonging drugs, and an additive effect cannot be excluded (ziprasidone SmPC, AEMPS). The documents describe no effect of either drug on the other's levels. The liver eliminates most quinidine through CYP3A4 (quinidine label, FDA). According to both of its documents, ziprasidone is unlikely to change the metabolism of drugs handled by CYP3A4 to a clinically relevant degree (ziprasidone SmPC, AEMPS; ziprasidone label, FDA).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Besides torsade de pointes, frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation have been reported with quinidine (quinidine label, US Food and Drug Administration, FDA). Bradycardia, low blood potassium, magnesium or calcium and high quinidine levels increase the risk of torsade de pointes, but it can also occur without any of these factors (quinidine label, FDA).
Management
The combination is contraindicated. The US ziprasidone label names quinidine among the drugs that ziprasidone should not be given with (ziprasidone label, US Food and Drug Administration, FDA). The Spanish ziprasidone summaries of product characteristics (SmPCs), for both the originator and the generic, contraindicate ziprasidone with QT-prolonging drugs and name class IA antiarrhythmics among them (ziprasidone SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS), the class that includes quinidine (quinidine label, FDA). The Spanish SmPCs also contraindicate ziprasidone in arrhythmias treated with class IA and III antiarrhythmics (ziprasidone SmPCs, AEMPS). Quinidine is not in the Spanish medicines register CIMA. If a person takes quinidine obtained in another country, do not prescribe ziprasidone with it (ziprasidone SmPCs, AEMPS; ziprasidone label, FDA). No document gives an interval between stopping quinidine and starting ziprasidone. The elimination half-life of quinidine in adults is 6–8 hours (quinidine label, FDA), and the mean terminal half-life of oral ziprasidone is 6.6 hours (ziprasidone SmPC, AEMPS). Correct low potassium and magnesium before starting ziprasidone. If the corrected QT interval (QTc) exceeds 500 ms, the SmPC recommends interrupting treatment (ziprasidone SmPC, AEMPS). If antiarrhythmic therapy is needed after a ziprasidone overdose, quinidine carries a theoretical risk of additive QT prolongation (ziprasidone label, FDA, overdose section). In haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and correct them aggressively where possible (quinidine label, FDA, overdose section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ziprasidona (nº registro 80960), sección 4.3 (2025)– AEMPS, CIMA, nº registro 80960, revisión 05/2025, sección 4.3
- AEMPS: Ficha técnica: Zeldox (ziprasidona) (nº registro 64851), secciones 4.3 y 4.4 (2025)– AEMPS, CIMA, nº registro 64851, revisión 06/2025, secciones 4.3, 4.4 y 4.5
- FDA: Geodon (ziprasidone) prescribing information (2025)– FDA, DailyMed, setid a2b4cc65-6a6d-49c4-adfc-a4458562a167, Viatris Specialty, Revised 1/2025, sections 4.1, 5.3, 7.3
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage